Icecure Medical Ltd Ord (ICCM)

$0.80 0.00 (-0.11%)
Market Cap 55.28M
Revenue (ttm) 3.29M
Net Income (ttm) -15.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -465.65%
Debt to Equity Ratio 0.70
Volume 398,400
Avg Vol 1,955,542
Day's Range N/A - N/A
Shares Out 68.70M
Stochastic %K 13%
Beta 0.31
Analysts Strong Sell
Price Target $2.91

Company Profile

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic...

Industry: Medical Devices
Sector: Healthcare
Phone: 972 4 623 0333
Fax: 972 4 623 0222
Address:
7 Ha’Eshel Street, PO Box 3163, Caesarea, Israel
BinaryLogic
BinaryLogic Oct. 25 at 7:59 PM
$ICCM [Strategy] Start/build/add $0.8 support line (look at 1YR Daily). 50-100% upside on positive catalyst(s) IMO as the Company continues to produce. Multiplier upside with commercial agreement and/or expansion (approval) to wider age range, new applications (lung, liver, kidney). Cryo-ablation is an incredibly interesting technology, ICCM owns the IP, success rates are consistently 90-99% in a litany of studies across multiple regions. In the interim-swing trade $0.8 to $1.5 (appx) until breakout occurs (IMO).
0 · Reply
Joe_088
Joe_088 Oct. 24 at 10:40 AM
$MBOT $ICCM
0 · Reply
Slitherin
Slitherin Oct. 23 at 1:43 PM
$GTIM shorts are trapped expect a big squeeze into market close and tomorrow. This is just the start. $ICCM $VTYX $SCNX $ARE on my radar too
0 · Reply
Joe_088
Joe_088 Oct. 23 at 7:53 AM
$MBOT $ICCM
0 · Reply
Safran18
Safran18 Oct. 23 at 7:29 AM
$ICCM blocked
0 · Reply
Whales22
Whales22 Oct. 23 at 5:55 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $NEXM $CIEN $ICCM $BIIB watchlist++
0 · Reply
Ragnarok_74
Ragnarok_74 Oct. 23 at 3:21 AM
$ICCM 🤡BLOCKED!
0 · Reply
bigcucus35
bigcucus35 Oct. 22 at 10:02 PM
$ICCM How has the stock price gone down as the company has improved. Genuine question. What is the catalyst
2 · Reply
Crimsonflare
Crimsonflare Oct. 22 at 3:54 PM
$ICCM very undervalued, this thing needs some traction.
0 · Reply
Joe_088
Joe_088 Oct. 22 at 9:36 AM
$MBOT $ICCM undervalued stock
0 · Reply
Latest News on ICCM
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

Oct 13, 2025, 8:30 AM EDT - 13 days ago

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

IceCure Medical to Attend the 2025 Maxim Growth Summit

Oct 9, 2025, 8:30 AM EDT - 17 days ago

IceCure Medical to Attend the 2025 Maxim Growth Summit

IceCure Medical Ltd - Special Call

Oct 6, 2025, 11:25 AM EDT - 19 days ago

IceCure Medical Ltd - Special Call

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Oct 3, 2025, 12:28 PM EDT - 22 days ago

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Oct 3, 2025, 12:19 PM EDT - 22 days ago

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

Sep 30, 2025, 8:30 AM EDT - 26 days ago

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

Sep 22, 2025, 8:30 AM EDT - 4 weeks ago

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

Sep 18, 2025, 8:30 AM EDT - 5 weeks ago

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Sep 15, 2025, 8:30 AM EDT - 5 weeks ago

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

Sep 8, 2025, 8:30 AM EDT - 6 weeks ago

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

Sep 4, 2025, 8:30 AM EDT - 7 weeks ago

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 1:08 PM EDT - 2 months ago

IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript

IceCure Reports Financial & Operational Results for the First Half of 2025

Aug 13, 2025, 8:30 AM EDT - 2 months ago

IceCure Reports Financial & Operational Results for the First Half of 2025

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

Aug 6, 2025, 8:30 AM EDT - 2 months ago

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

Jul 29, 2025, 9:00 AM EDT - 3 months ago

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

Jul 25, 2025, 9:00 AM EDT - 3 months ago

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

Jul 24, 2025, 9:00 AM EDT - 3 months ago

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

IceCure Announces Commencement of Rights Offering

Jul 10, 2025, 8:00 AM EDT - 3 months ago

IceCure Announces Commencement of Rights Offering

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

Jul 3, 2025, 8:30 AM EDT - 4 months ago

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

IceCure Announces Record Date for Rights Offering for Up to $10 Million

Jun 25, 2025, 9:23 AM EDT - 4 months ago

IceCure Announces Record Date for Rights Offering for Up to $10 Million

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

Jun 9, 2025, 8:30 AM EDT - 4 months ago

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript

May 28, 2025, 4:26 PM EDT - 5 months ago

IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript

IceCure Medical Reports First Quarter 2025 Financial Results

May 28, 2025, 8:30 AM EDT - 5 months ago

IceCure Medical Reports First Quarter 2025 Financial Results

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

May 21, 2025, 8:30 AM EDT - 5 months ago

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

May 6, 2025, 8:30 AM EDT - 6 months ago

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

Apr 30, 2025, 8:30 AM EDT - 6 months ago

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

Apr 28, 2025, 8:30 AM EDT - 6 months ago

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

Apr 22, 2025, 8:30 AM EDT - 6 months ago

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 1:45 PM EDT - 7 months ago

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

Mar 27, 2025, 8:30 AM EDT - 7 months ago

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Mar 24, 2025, 8:30 AM EDT - 7 months ago

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

Mar 21, 2025, 8:30 AM EDT - 7 months ago

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

Mar 20, 2025, 8:30 AM EDT - 7 months ago

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

Mar 18, 2025, 8:30 AM EDT - 7 months ago

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Mar 17, 2025, 8:30 AM EDT - 7 months ago

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

Mar 10, 2025, 8:30 AM EDT - 8 months ago

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

Feb 24, 2025, 8:30 AM EST - 8 months ago

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

Feb 4, 2025, 8:30 AM EST - 9 months ago

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

Jan 27, 2025, 8:30 AM EST - 9 months ago

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

Jan 13, 2025, 7:00 AM EST - 10 months ago

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

Jan 6, 2025, 8:30 AM EST - 10 months ago

IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology

Jan 3, 2025, 8:30 AM EST - 10 months ago

European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

Dec 16, 2024, 8:30 AM EST - 11 months ago

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript

Nov 26, 2024, 1:46 PM EST - 11 months ago

IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript

IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation

Nov 26, 2024, 8:30 AM EST - 11 months ago

IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation

IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

Nov 25, 2024, 8:30 AM EST - 11 months ago

IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

Nov 20, 2024, 8:30 AM EST - 1 year ago

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

Nov 19, 2024, 8:30 AM EST - 1 year ago

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer

Nov 8, 2024, 7:00 AM EST - 1 year ago

FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer

Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders

Oct 29, 2024, 8:30 AM EDT - 1 year ago

Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders

BinaryLogic
BinaryLogic Oct. 25 at 7:59 PM
$ICCM [Strategy] Start/build/add $0.8 support line (look at 1YR Daily). 50-100% upside on positive catalyst(s) IMO as the Company continues to produce. Multiplier upside with commercial agreement and/or expansion (approval) to wider age range, new applications (lung, liver, kidney). Cryo-ablation is an incredibly interesting technology, ICCM owns the IP, success rates are consistently 90-99% in a litany of studies across multiple regions. In the interim-swing trade $0.8 to $1.5 (appx) until breakout occurs (IMO).
0 · Reply
Joe_088
Joe_088 Oct. 24 at 10:40 AM
$MBOT $ICCM
0 · Reply
Slitherin
Slitherin Oct. 23 at 1:43 PM
$GTIM shorts are trapped expect a big squeeze into market close and tomorrow. This is just the start. $ICCM $VTYX $SCNX $ARE on my radar too
0 · Reply
Joe_088
Joe_088 Oct. 23 at 7:53 AM
$MBOT $ICCM
0 · Reply
Safran18
Safran18 Oct. 23 at 7:29 AM
$ICCM blocked
0 · Reply
Whales22
Whales22 Oct. 23 at 5:55 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $NEXM $CIEN $ICCM $BIIB watchlist++
0 · Reply
Ragnarok_74
Ragnarok_74 Oct. 23 at 3:21 AM
$ICCM 🤡BLOCKED!
0 · Reply
bigcucus35
bigcucus35 Oct. 22 at 10:02 PM
$ICCM How has the stock price gone down as the company has improved. Genuine question. What is the catalyst
2 · Reply
Crimsonflare
Crimsonflare Oct. 22 at 3:54 PM
$ICCM very undervalued, this thing needs some traction.
0 · Reply
Joe_088
Joe_088 Oct. 22 at 9:36 AM
$MBOT $ICCM undervalued stock
0 · Reply
KobiZholtack
KobiZholtack Oct. 22 at 9:12 AM
$ICCM https://ir.icecure-medical.com/news-events/press-releases/detail/192/icecure-medical-to-attend-the-2025-maxim-growth-summit Today.
0 · Reply
Bbking241
Bbking241 Oct. 21 at 3:09 PM
$ICCM The stock that never moves. I can sleep for days and not a thing would have changed in the movement of the price.
0 · Reply
Tom678
Tom678 Oct. 21 at 1:16 PM
$ICCM $MBOT
0 · Reply
Joe_088
Joe_088 Oct. 21 at 10:24 AM
$ICCM $MBOT
0 · Reply
TheJunksCalls
TheJunksCalls Oct. 20 at 8:08 PM
$KUKE <~~ 💥🔫 Easy Money. 70% swing trade✅ Clowns reported my last post because there is no one better to do it. Study plays and keep them in rotation every year. Again, this was free money. Straight up shot from .75–>$1.00 exactly at 3:52 like I said it would. Alerted Friday and this morning. $REI $ESPR $ICCM $BULL <~~ All my long plays will double in due time. Don’t sleep 💤
0 · Reply
Joe_088
Joe_088 Oct. 20 at 7:56 PM
$ICCM
0 · Reply
TheJunksCalls
TheJunksCalls Oct. 20 at 1:20 PM
$KUKE <~~ Rinse & Repeat Play Every Year✅ KUKE went straight up everyday before market closed for weeks straight. I’m talking 10%+ everytime starting at 3:50 ET for the last couple years. After the loading was done it went up 200%+. Once it regains compliance it’s back in the dumps before they run it up again. This will run over $1+ any day/week. Process doesn’t chang here. $BULL $REI $ICCM $CNTX Long Plays 👊🏻
1 · Reply
Joe_088
Joe_088 Oct. 20 at 12:21 PM
$MBOT $ICCM
0 · Reply
Tom678
Tom678 Oct. 20 at 9:35 AM
$ICCM agree 👍
0 · Reply
Logan93
Logan93 Oct. 18 at 2:40 PM
$ICCM best way I’ve found to play this is to have firm mental stops and utilize them. For example, when I bought at .998 I stopped out at .97 and when I bought back in at .87 I stopped out at .84 ..still a loss but not as bad as if I would have held. Not sure if we’re at bottom yet but I bought back in yesterday at .806 and my current stop is .78 area. Still believe in this long term.
1 · Reply
kingfroggy99
kingfroggy99 Oct. 18 at 6:01 AM
$ICCM oversold bounce soon
0 · Reply
checkmate35
checkmate35 Oct. 17 at 10:00 PM
$ICCM tremendous potential - the risk vs reward is very favorable to me. I will be patient.
1 · Reply